<SEC-DOCUMENT>0001213900-18-009608.txt : 20180725
<SEC-HEADER>0001213900-18-009608.hdr.sgml : 20180725
<ACCEPTANCE-DATETIME>20180725092245
ACCESSION NUMBER:		0001213900-18-009608
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20180702
FILED AS OF DATE:		20180725
DATE AS OF CHANGE:		20180725

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Pearson Mark E.
		CENTRAL INDEX KEY:			0001486558

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14778
		FILM NUMBER:		18967818

	MAIL ADDRESS:	
		STREET 1:		3031 TISCH WAY
		STREET 2:		SUITE 505
		CITY:			SAN JOSE
		STATE:			CA
		ZIP:			95128

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SOLIGENIX, INC.
		CENTRAL INDEX KEY:			0000812796
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				411505029
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		29 EMMONS DRIVE
		STREET 2:		SUITE B-10
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		609-538-8200

	MAIL ADDRESS:	
		STREET 1:		29 EMMONS DRIVE
		STREET 2:		SUITE B-10
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DOR BIOPHARMA INC
		DATE OF NAME CHANGE:	20020329

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENDOREX CORP
		DATE OF NAME CHANGE:	19960916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2018-07-02</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000812796</issuerCik>
        <issuerName>SOLIGENIX, INC.</issuerName>
        <issuerTradingSymbol>SNGX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001486558</rptOwnerCik>
            <rptOwnerName>Pearson Mark E.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>29 EMMONS DRIVE, SUITE B-10</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PRINCETON</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08540</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>COMMON STOCK</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2330000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>WARRANT (RIGHT TO BUY)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.25</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2018-07-02</value>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2022-01-02</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>COMMON STOCK</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>932000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The warrant currently is exercisable, subject to a blocker provision that prevents the holder from exercising the warrant if such holder would beneficially own in excess of 4.99% of the issuer's common stock following such exercise.</footnote>
        <footnote id="F2">These securities are held by Altamont Pharmaceutical Holdings, LLC, a company for which the reporting person serves as general partner and chief executive officer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Mark E. Pearson</signatureName>
        <signatureDate>2018-07-24</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
